Chimigen Bio
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Chimigen Bio - overview
Established
2021
Location
Chengdu, Sichuan, China
Primary Industry
Biotechnology
About
Based in Chengdu, China, and founded in 2021, Chimigen Bio is a developer of immunotherapy, focusing on antiviral and antitumor immunotherapy development. The founder Dr. Yuenian Shi graduated from Beijing Medical University and has focused on oncology research for nearly 35 years. In February 2025, it closed a venture funding led by new investor SDIC Venture Capital, with participation from other new investor Casstar Capital.
The company has developed a series of antigen-specific immunotherapies against viruses and tumors with the support of the SynNeogen technology platform. The products are focused on unmet clinical needs in hepatitis B and prostate cancer. The core innovative vaccine platform, SynNeogen mimics the body's natural antigen uptake, processing and presentation processes and further induces antigen-specific, multi-epitope immune responses. The company generates revenue by developing antiviral and anti-tumor immunotherapy.
The company will use the funds to accelerate the global clinical development of its core products SN3001 (prostate cancer therapeutic vaccine) and SN2001 (chronic hepatitis B immunotherapy vaccine). In July 2025, Chimigen Bio raised CNY 170 million of Pre-A funding, which was jointly led by returning investor SDIC Venture Capital, followed by returning investors Casstar Capital, Lapam Capital and new investor BIO-TOWN Capital.
Current Investors
Puhua Capital, Nanjing King-friend Biochemical Pharmaceutical Co., Ltd, Lapam Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.chimigen.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.